Clinical Trial Update: A Post Marketing Surveillance (PMS) Study to Monitor the Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine in Female Chinese Subjects

View source ↗

Summary

A post-marketing surveillance study assessing the safety of GSK's HPV vaccine in female Chinese participants has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Intraepithelial Neoplasia

Drugs mentioned

• HPV vaccine

Snippet

Sponsor: GlaxoSmithKline | Conditions: Cervical Intraepithelial Neoplasia | Status: COMPLETED | Results posted: 2021-09-08